学术探索
学术期刊
新闻热点
数据分析
智能评审

The potential role of bisphosphonates in prostate cancer

被引：37
作者：
Oades, GM
Coxon, J
Colston, KW
机构：
[1] Univ London St Georges Hosp, Dept Urol, London, England
[2] Univ London St Georges Hosp, Dept Oncol Gastroenterol Endocrinol & Metab, London, England
[3] Univ London Sch Med, London, England
来源：
PROSTATE CANCER AND PROSTATIC DISEASES | 2002年 / 5卷 / 04期
关键词：
bisphosphonates; bone; metastases; prostate cancer;
D O I：
10.1038/sj.pcan.4500607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphonates in addition to their role in inhibiting osteoclast mediated bone resorption. Both preclinical and clinical evidence of a role for bisphosphonates in the treatment and prevention of bone metastases secondary to prostate cancer is assessed.
引用
收藏
页码：264 / 272
页数：9
相关论文
共 99 条
  • [71] Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO
  • [72] 2-Z
  • [73] Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial
    Saarto, T
    Blomqvist, C
    Virkkunen, P
    Elomaa, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) : 10 - 17
  • [74] Selander KS, 1996, MOL PHARMACOL, V50, P1127
  • [75] Bisphosphonates induce apoptosis in human breast cancer cell lines
    Senaratne, SG
    Pirianov, G
    Mansi, JL
    Arnett, TR
    Colston, KW
    [J]. BRITISH JOURNAL OF CANCER, 2000, 82 (08) : 1459 - 1468
  • [76] SENARATNE SG, 2001, P AM ASS CANC RES
  • [77] Shipman CM, 1998, CANCER RES, V58, P5294
  • [78] Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
    Simonet, WS
    Lacey, DL
    Dunstan, CR
    Kelley, M
    Chang, MS
    Luthy, R
    Nguyen, HQ
    Wooden, S
    Bennett, L
    Boone, T
    Shimamoto, G
    DeRose, M
    Elliott, R
    Colombero, A
    Tan, HL
    Trail, G
    Sullivan, J
    Davy, E
    Bucay, N
    RenshawGegg, L
    Hughes, TM
    Hill, D
    Pattison, W
    Campbell, P
    Sander, S
    Van, G
    Tarpley, J
    Derby, P
    Lee, R
    Boyle, WJ
    [J]. CELL, 1997, 89 (02) : 309 - 319
  • [79] PALLIATION OF PAINFUL BONE METASTASES FROM PROSTATE-CANCER USING SODIUM ETIDRONATE - RESULTS OF A RANDOMIZED, PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    SMITH, JA
    [J]. JOURNAL OF UROLOGY, 1989, 141 (01) : 85 - 87
  • [80] Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
    Smith, MR
    McGovern, FJ
    Zietman, AL
    Fallon, MA
    Hayden, DL
    Schoenfeld, DA
    Kantoff, PW
    Finkelstein, JS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (13) : 948 - 955
12345678910